Nepal | September 30, 2020

Drug can curb dementia’s delusions, researchers find

ASSOCIATED PRESS
Share Now:

SAN DIEGO: A drug that curbs delusions in Parkinson’s patients did the same for people with Alzheimer’s disease and other forms of dementia in a study that was stopped early because the benefit seemed clear.

If regulators agree, the drug could become the first treatment specifically for dementia-related psychosis and the first new medicine for Alzheimer’s in nearly two decades. It targets some of the most troubling symptoms that patients and caregivers face — hallucinations that often lead to anxiety, aggression, and physical and verbal abuse.

Results were disclosed Wednesday at a conference in San Diego.

“This would be a very important advance,” said one independent expert, Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation.

Although the field is focused on finding a cure for dementia and preventing future cases, “there is a huge unmet need for better treatment” for those who have it now, said Maria Carrillo, the Alzheimer’s Association’s chief science officer.

The drug is pimavanserin, a daily pill sold as Nuplazid by Acadia Pharmaceuticals Inc. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions.

About 8 million Americans have dementia, and studies suggest that up to 30% of them develop psychosis.

“It’s terrifying,” said Dr. Jeffrey Cummings of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. “You believe that people might be trying to hurt you. You believe that people are stealing from you. You believe that your spouse is unfaithful to you. Those are the three most common false beliefs.”

He consults for Acadia and helped lead the study, which included about 400 people with dementia and psychosis. All were given a low dose of the drug for three months, and those who seemed to respond or benefit were then split into two groups. Half continued on the drug and the others were given dummy pills for six months or until they had a relapse or worsening of symptoms. Neither the patients nor their doctors knew who was getting what.

Independent monitors stopped the study when they saw that those on dummy pills were more than twice as likely as those on the drug to relapse or worsen — 28% versus nearly 13%.

There were relatively few serious side effects — 5% in the drug group and 4% in the others. Headaches and urinary tract infections were more common among those on the drug. Two deaths occurred, but study leaders said neither was related to the drug.

Carrillo said the study was small, but the drug’s effect seemed large, and it’s not known whether the federal Food and Drug Administration would want more evidence to approve a new use.

Current anti-psychotic medicines have some major drawbacks and are not approved for dementia patients.

“They’re often used off label because we have very few other options,” Fillit said.

All carry warnings that they can raise the risk of death in elderly patients, as does Nuplazid.

Cost could be an issue — about $3,000 a month. What patients pay can vary depending on insurance coverage.


Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

Woman found dead in Saptari district

A police team has been deployed from Province Police Office, Janakpur, to investigate the case RAJBIRAJ, SEPTEMBER 28 A 50-year-old woman was found dead at Mayanakaderi village, Ward No 2 of Tirhut Rural Municipality, Saptari, yesterday. The body of Dayaman Devi, wife of local Shiv Narayan, w Read More...

TU likely to conduct exams after Dashain, Tihar festivals

KATHMANDU, SEPTEMBER 28 Tribhuvan University has decided to conduct its regular examinations after the upcoming festivals by adding more examination centres and allowing students to take exams from the nearest examination centres. TU is all set to publish the exam routine very soon. The cou Read More...

Dr KC’s supporters move NHRC against CDO, police chief

KATHMANDU, SEPTEMBER 28 Supporters of Dr Govinda KC have filed a complaint with the National Human Right Commission against Kathmandu’s Chief District Officer Janak Raj Dahal and head of Metropolitan Police Range’s SSP Shyam Lal Gyawali. Members of ‘solidarity for Govinda KC’ filed the Read More...

Sanphe-Martadi road obstructed for months

BAJURA, SEPTEMBER 28 Sanphe-Martadi road section has been obstructed for the last three months due to landslides in different places along the road section in Bajura. The road section from Barjugard to Martadi was obstructed due to incessant rainfall following mud slips in many places. The Read More...

THT logo

KTM 390 Adventure rolls out in Nepal

KATHMANDU: KTM, the world’s number one and Nepal’s fastest growing premium motorcycle brand, has launched the most awaited KTM 390 Adventure in the country. The bike can be bought at KTM showrooms across the country for the introductory price of Rs 999,000, as per a media release. KTM 390 Advent Read More...

THT logo

NMB Bank joins PCAF

KATHMANDU: NMB Bank has joined the Partnership for Carbon Accounting Financials (PCAF), an industry-led initiative to measure and disclose greenhouse gas emissions financed by loans and investments. PCAF has grown rapidly, as per a press statement. From 50 financial institutions with over $5 tril Read More...

BPKIHS reports one more Covid-19 related fatality on Tuesday

KATHMANDU: The Dharan-based BP Koirala Institute of Health Sciences (BPKIHS) has reported a new Covid-19 related death on Tuesday. According to BPKIHS, the 68-year-old male of Sunbarshi-7 of Morang district passed away while undergoing treatment at the COVID Hospital of the institute at 3:00 am t Read More...

Australia's Perry out of NZ series after re-injuring hamstring

MELBOURNE: Australia all-rounder Ellyse Perry has been ruled out of the remaining limited overs series against New Zealand after re-injuring her hamstring, the team said on Tuesday. Perry, who tore her right hamstring during the Women's Twenty20 World Cup in Australia earlier this year, had h Read More...